Company News
Gain Therapeutics Gains 21% After FDA IND Clearance
Gain Therapeutics shares jumped 21.2% in after‑hours trading after the FDA cleared its IND for GT‑02287, a Parkinson’s drug.
The IND permits a Phase 2a trial in the U.S., Australia and Europe slated f
